Researchers assessed the outcomes of all patients admitted to University of Alabama at Birmingham Medical Center from 2005 to 2008 to determine whether antimicrobial use was associated with increased risk or incidence of VRE bloodstream infections.
They found prior-month usage of the antibiotics piperacillin-tazobactam, ceftazidime, cefepime, cefazolin or vancomycin was not predictive of VRE bloodstream infection. However use of antimicrobial ceftriaxone in the prior month was associated with increased incidence of VRE bloodstream infection. Researchers concluded lower use of this type of antimicrobial may improve infection prevention efforts.
Related Articles on Antimicrobial Stewardship:
Antimicrobial Stewardship Programs Reduce CDI Rates, Healthcare Costs
Antimicrobial Resistance to Common UTI Drug Increases 5-Fold
FDA Takes Steps to Foster Judicious Antimicrobial Use
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
